[Allo-geneic hematopoietic stem cell transplantation in treatment with XXXX mutation of @entity1860 ].

@entity1 @entity1667 @entity870 @entity28837 @entity205 @entity2098 @entity2132 @entity381 @entity618 @entity358 @entity676 @entity1864 @entity28835 @entity1860 @entity2213
OBJECTIVE: To explore the therapeutic efficacy of allo-geneic hematopoietic stem cell transplantation (allo-HSCT) for @entity1860 ( @entity1860 ) @entity1 with @entity28837 mutation. METHODS: Retrospective analyses were conducted for 4 @entity1 with @entity28837 mutation of @entity1860 undergoing allo-HSCT from June 2012 to January 2014, including 2 cases in acceleration phase and 2 in chronic phase. There were 2 males and 2 females with ages from 26 to 45 years. Two @entity1 received HLA-matched sibling allo-geneic peripheral blood stem cell transplantation (allo-PBSCT) while another 2 unrelated cord blood stem cell transplantation (UCBT). No @entity381 was found before transplantation. One case had @entity28835 mutation. All of them were treated with @entity2213 before transplantation. And the time from medication to @entity28837 mutation was 20-35 months. All of them were conditioned with myeloablative regimen and received a combination of @entity205 ( @entity870 ) and @entity618 ( @entity2098 ) for preventing @entity2132 ( @entity2132 ). RESULTS: Myeloid implantation was achieved in all of them. The time of absolute neutrophil count (ANC) >=  0.5*10(9)/L were 10-28 days. One @entity1 whose platelet was not implanted died from severe @entity358 at Day 88 post-transplantation. For 3 @entity1 , platelet >=  20*10(9)/L were 15-33 days. But the marrow short tandem repeat (STR)-PCR was 100% donor type at the time of 30 days post-transplantation in all @entity1 . One case of UCBT developed pre-implantation immune response syndrome (PES) and one acute @entity2132 of gradeI at Day 12 after allo-PBSCT. However both were controlled after treatment with @entity1667 . @entity676 /3 evaluatable @entity1 developed chronic @entity2132 . @entity1864 transcript was detected by qualitative PCR after transplantation. And all @entity1864 fusion genes turned negative after 30 days of transplantation. Up to the follow-up endpoint, there was no relapse except for one mortality. And the time of disease-free survival was 133, 248 and 704 days respectively. CONCLUSIONS: Allo-HSCT is currently the optimal treatment for @entity28837 mutation of @entity1860 . And umbilical cord blood is an ideal donor for those @entity1 without HLA-matched sibling donor.
